Key Highlights
- Shares of AEHR declined 9.1% to close at $132.37 during Tuesday’s session, accompanied by sharply reduced trading volume
- Wall Street analysts maintain a consensus “Buy” recommendation with an average price target of $136.67
- Jefferies recently launched coverage with a “Buy” rating and established a $175 price objective
- Company insiders liquidated 109,475 shares valued at approximately $13.8 million in the last three months
- Institutional ownership stands at approximately 69.7%, with major holders including Vanguard and UBS
Shares of Aehr Test Systems (AEHR) experienced a sharp decline of 9.1% during Tuesday’s trading session, settling at $132.37. This represented a significant pullback from the prior day’s closing price of $145.61.
Trading activity was markedly subdued during the session. Approximately 520,330 shares exchanged hands, representing a dramatic 79% decline compared to the typical daily volume of 2,424,321 shares.
The stock’s 12-month performance illustrates remarkable volatility. Over the past year, AEHR has traded as low as $16.38 and reached a peak of $147.40, a level achieved in recent sessions.
At present trading levels, the semiconductor testing company commands a market capitalization of approximately $4.03 billion. The stock exhibits a P/E ratio of -519.12 and a beta coefficient of 3.10, underscoring its tendency toward significant price fluctuations.
Wall Street Maintains Bullish Stance
Tuesday’s decline hasn’t shaken analyst confidence in AEHR. The stock continues to carry a collective “Buy” recommendation from the analyst community, with price targets averaging $136.67.
This week saw Jefferies launch coverage on the stock with a “Buy” rating alongside an ambitious $175 price objective. This represents one of the most optimistic projections currently on the Street.
Freedom Capital and Zacks Research both elevated their ratings to “Strong Buy” in July. Meanwhile, Wall Street Zen shifted its stance from “Sell” to “Hold” during the same period.
Craig Hallum maintained its “Buy” recommendation in July, establishing a $125 price objective. Conversely, Weiss Ratings took a more pessimistic view, lowering its rating from “Sell (D)” to “Sell (E+)” at July’s conclusion.
Among the seven analysts providing coverage, two assign “Strong Buy” ratings, four recommend “Buy,” and one maintains a “Sell” rating.
Executive Stock Sales Raise Eyebrows
Recent insider transactions have attracted significant attention. During the past three months, company insiders divested a total of 109,475 shares valued at approximately $13.8 million.
Chief Operating Officer Adil Engineer executed a sale of 15,000 shares on August 12 at an average price of $131.02, generating proceeds of $1.97 million. This transaction reduced his holdings by 24.2%.
Executive Vice President Alberto Salamone sold 9,672 shares on August 13 at $127.72 per share, realizing approximately $1.24 million. His ownership stake decreased by 18.7%.
Board Director Howard T. Slayen disposed of 20,000 shares on August 4 at $108.30 each, a sale valued at $2.17 million. This reduced his holdings by roughly 12%.
Company insiders collectively maintain 6.8% ownership of Aehr Test Systems.
Among institutional investors, Royal Bank of Canada expanded its position by 15.3% during the first quarter, acquiring 7,968 additional shares for a total of 59,939. Vanguard Group increased its stake by 2.2%, while UBS elevated its holdings by 55.7%. Institutional investors collectively control 69.69% of outstanding shares.
The stock’s 50-day moving average currently sits at $93.83, while the 200-day moving average rests at $72.59, both substantially below today’s trading price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
